Consensus guideline on parenteral methadone use in pain and palliative care

Once used only as third-line therapy for chronic pain management, methadone is now being used as first- and second-line therapy in palliative care. The risks and stigma associated with methadone use are known, but difficulties with dosing methadone and lack of an established conversion protocol from...

Full description

Saved in:
Bibliographic Details
Published inPalliative & supportive care Vol. 6; no. 2; pp. 165 - 176
Main Authors Shaiova, Lauren, Berger, Ann, Blinderman, Craig D., Bruera, Eduardo, Davis, Mellar P., Derby, Susan, Inturrisi, Charles, Kalman, Jill, Mehta, Davendra, Pappagallo, Marco, Perlov, Eugene
Format Journal Article
LanguageEnglish
Published New York, USA Cambridge University Press 01.06.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Once used only as third-line therapy for chronic pain management, methadone is now being used as first- and second-line therapy in palliative care. The risks and stigma associated with methadone use are known, but difficulties with dosing methadone and lack of an established conversion protocol from other opiates have limited the access for patient populations who could potentially benefit from this medication. For palliative care patients, the benefits of methadone can far outweigh its risks. This article provides an overview and specific recommendations on the use of parenteral methadone in pain and palliative care, with a focus on the transition from hospital to home/hospice care. The goal of this consensus guideline is to assist clinicians who are providing chronic pain management in acute care hospital and nonhospital settings (i.e., hospice, long-term care facilities, and community) for patients with life-limiting illnesses, where the goals of care are focused on comfort (i.e., palliative care). The recommendations in this article intend to promote a standard of care involving the use of intravenous methadone with the aim of reaching a broader population of patients for whom this drug would provide important benefits.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1478-9515
1478-9523
DOI:10.1017/S1478951508000254